Poor glycaemic control in type 2 diabetes (T2D) is a global problem despite the availability
of numerous glucose‐lowering therapies and clear guidelines for T2D management …

Many people with type 2 diabetes mellitus (T2DM) fail to achieve glycaemic control promptly
after diagnosis and do not receive timely treatment intensification. This may be in part due to …

Aim To investigate whether clinical inertia, the failure to intensify treatment regimens when
required, exists in people with type 2 diabetes treated with basal insulin. Methods This was a …

Theranostic nanoplatforms with integrated diagnostic and therapeutic functions, aiming at
imaging‐guided therapy to improve treatment planning, as well as combination therapy to …

Achieving tight glycaemic control early following the diagnosis of type 2 diabetes is key to
optimising clinical outcomes, yet many patients and clinicians are reluctant to initiate and …

Aims/hypothesis We evaluated the secular trend of glycaemic control in individuals with type
2 diabetes in developing countries, where data are limited. Methods The International …

Diabetes mellitus is a chronic disease characterized by high social, economic and health
burden, mostly due to the high incidence and morbidity of diabetes complications …

Aims To describe the characteristics and treatment of patients with type 2 diabetes mellitus
initiating a second-line glucose-lowering therapy in the global DISCOVER study …

Aims To evaluate short‐and long‐term glycaemic control and hypoglycaemia incidence in
insulin‐naïve patients≥ 30 years of age with type 2 diabetes (T2DM) initiating basal insulin …

Research has shown that getting to glycemic targets early on leads to better outcomes in
people with type 2 diabetes; yet, there has been no improvement in the attainment of A1C …